74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Prothena Corp PLC
Closed
SectorHealthcare
9.63 0.73
Overview
Share price change
24h
Min
9.41
Max
9.96
Income | 1M -58M |
|---|---|
Sales | 1.2M 2.1M |
EPS | -1.08 |
Profit margin | -2,729.911 |
Employees | 163 |
EBITDA | 1.6M -65M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +465.49% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | -264M 501M |
|---|---|
Previous open | 8.9 |
Previous close | 9.63 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Prothena Corp PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Prothena Corp PLC Forecast
Price Target
By TipRanks
465.49% upside
12 Months Forecast
Average 54.57 USD 465.49%
High 110 USD
Low 20 USD
Based on 8 Wall Street analysts offering 12 month price targets forProthena Corp PLC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Prothena Corp PLC
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
